Free Trial

Keros Therapeutics (KROS) SEC Filings & 10K Form

Keros Therapeutics logo
$14.30 +0.41 (+2.95%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$14.30 +0.00 (+0.03%)
As of 04/23/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Keros Therapeutics SEC Filings

DateFilerForm TypeView
04/23/2025
3:09 PM
Keros Therapeutics (Filer)
Form ARS
04/23/2025
3:03 PM
Keros Therapeutics (Filer)
Form DEF 14A
04/11/2025
8:57 PM
ADAR1 Capital Management GP, LLC (Reporting)
ADAR1 Capital Management, LLC (Reporting)
ADAR1 Partners, LP (Reporting)
Keros Therapeutics (Issuer)
Schneeberger Daniel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/11/2025
7:58 PM
ADAR1 Capital Management GP, LLC (Reporting)
ADAR1 Capital Management, LLC (Reporting)
ADAR1 Partners, LP (Reporting)
Keros Therapeutics (Issuer)
Schneeberger Daniel (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/11/2025
7:32 PM
ADAR1 Capital Management, LLC (Filed by)
Keros Therapeutics (Subject)
Form SCHEDULE 13D
04/10/2025
5:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2025
5:04 AM
Keros Therapeutics (Filer)
Form 8-A12B
04/07/2025
3:15 PM
Keros Therapeutics (Issuer)
Seehra Jasbir (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2025
5:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/28/2025
4:01 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/07/2025
9:23 AM
FMR LLC (Filed by)
Keros Therapeutics (Subject)
Form SCHEDULE 13G/A
01/30/2025
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/24/2025
3:15 PM
Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
Form 4/A
01/21/2025
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/15/2025
5:31 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/10/2025
7:00 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/12/2024
5:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2024
6:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/08/2024
3:18 PM
CHYUNG YUNG H. (Reporting)
Keros Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
11/06/2024
3:22 PM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2024
7:00 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/28/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2024
4:06 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2024
4:01 PM
Keros Therapeutics (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VII LLC (Reporting)
OrbiMed Genesis GP LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:12 PM
Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:02 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
4:15 PM
Keros Therapeutics (Filer)
Form 424B5
06/17/2024
4:17 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
5:07 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
3:10 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/05/2024
3:11 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2024
3:15 PM
Farzan Nima (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GRAY MARY ANN (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Knowles Julius (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Nussbaum Ran (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
This Crypto Is Set to Explode in January (Ad)

The crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds.

Click here to reserve your seat now.
06/03/2024
3:15 PM
Kariv Tomer (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Seth Alpna (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:03 AM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/03/2024
7:00 AM
Keros Therapeutics (Filer)
Form S-3ASR
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:KROS) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners